Literature DB >> 8602613

Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears.

S K Apple1, J R Hecht, J M Novak, R K Nieberg, D L Rosenthal, W W Grody.   

Abstract

The cytologic diagnosis of pancreatic carcinoma is notoriously difficult, particularly in distinguishing benign atypia from well-differentiated adenocarcinoma. Mutation of codon 12 in the K-ras oncogene is frequently found with pancreatic cancers. Detection by polymerase chain reaction (PCR) followed by restriction endonuclease digestion can provide a powerful tool to improve and confirm diagnosis. The authors examined the utility of PCR-based detection in the diagnosis of pancreatic carcinoma using routinely obtained cytology smears that could be collected at most hospitals. Pancreatic cytology smears were collected retrospectively from 60 patients. DNA was extracted from the slides and amplified by PCR using mismatched primers that generated a Bst-N1 recognition site with the wild type codon 12 but not with the mutant allele. Results were compared with clinical follow-up. K-ras codon 12 mutations were observed in 44 of 46 (95.7%) cases of pancreatic cancer, but not in 12 benign cases nor in 2 cases of islet cell tumor. The amplification and digestion steps proved robust and sensitive, capable of detecting mutant K-ras alleles from cytology smears that contained only small foci of suspicious cells. Our results indicate that K-ras mutation analysis can be done reliably within 1 to 2 days from routine cytology slides without special handling, increasing the sensitivity of diagnosis in ambiguous cases while maintaining cost-effective and relatively noninvasive sampling strategy.

Entities:  

Mesh:

Year:  1996        PMID: 8602613     DOI: 10.1093/ajcp/105.3.321

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients.

Authors:  R H Hruban; P D Sturm; R J Slebos; R E Wilentz; A R Musler; C J Yeo; T A Sohn; M L van Velthuysen; G J Offerhaus
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 3.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

4.  Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum.

Authors:  L Theodor; E Melzer; M Sologov; G Idelman; E Friedman; S Bar-Meir
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

Review 5.  Molecular diagnosis of pancreas carcinoma.

Authors:  T M Chu
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  The Significance of p53 and K-ras Immunocytochemical Staining in the Diagnosis of Malignant Biliary Obstruction by Brush Cytology during ERCP.

Authors:  Young Sup Kim; Ho Gak Kim; Jimin Han; Change Jae Hur; Byeong Suk Kim; Jin Tae Jung; Joong Goo Kwon; Eun Young Kim; Chang-Ho Cho; Yoon Kyung Sohn
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

7.  Molecular beacon imaging of tumor marker gene expression in pancreatic cancer cells.

Authors:  Lily Yang; Zehong Cao; Yiming Lin; William C Wood; Charles A Staley
Journal:  Cancer Biol Ther       Date:  2005-05-20       Impact factor: 4.742

Review 8.  Current approaches to novel therapeutics in pancreatic cancer.

Authors:  Corina E Akerele; Irina Rybalova; Howard L Kaufman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

9.  K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas.

Authors:  D Bartsch; D Bastian; P Barth; A Schudy; C Nies; O Kisker; H J Wagner; M Rothmund
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

10.  High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

Authors:  Michael Krypuy; Genni M Newnham; David M Thomas; Matthew Conron; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2006-12-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.